New application in the RIM suite to unify publishing capabilities and content management,
from planning through archival, within a single cloud platform
Pleasanton, CA - Veeva Systems today announced Veeva Vault Submissions Publishing, a new cloud application that seamlessly incorporates publishing capabilities within Veeva Vault RIM to speed regulatory submission delivery. The addition of Vault Submissions Publishing unifies publishing capabilities and enterprise content management to streamline end-to-end submission development. Now life sciences companies can plan, review, publish, archive, and validate submissions within a single cloud platform.
Traditionally, regulatory submissions are created with disparate systems for content management and publishing. Working with separate systems requires file transfers and impedes the publishing team’s visibility into document readiness, making it difficult to effectively plan and allocate resources.
“Submission planning, registration tracking, document management, and publishing are all within one end-to-end process,” said Steve Gens, managing partner at Gens and Associates. “Having publishing within a set of unified regulatory capabilities can reduce cycle times and improve productivity throughout the entire submission development process.”
Veeva Vault Submissions Publishing empowers publishing teams to perform activities during document authoring, formatting, and reviews. This enables a continuous publishing process instead of waiting for the submission plan and documents to be finalized. With activities such as document hyperlinking and validation now moved upstream and automated, teams can complete work faster and speed submission development.
“The industry struggles with disjointed systems that force regulatory teams to duplicate data, documents, and effort,” said Frank Bosley, vice president, global head of regulatory operations at The Medicines Company. “A unified RIM approach like Veeva's can streamline submission preparation and enable sponsors to reduce risk and delays.”
Veeva Vault Submissions Publishing together with Vault Registrations, Vault Submissions, and Vault Submissions Archive delivers a unified RIM suite for seamless information and traceability throughout RIM processes.
“RIM transformation is gaining considerable momentum as companies seek greater visibility and global alignment across regulatory,” said John Lawrie, vice president, Veeva Vault RIM, at Veeva. “Now, with end-to-end submission development, regulatory can speed submission delivery and gain complete traceability between source documents, filed dossiers, and related product registrations.”
Veeva Vault Submissions Publishing is planned for availability in early 2018.
Additional Information
For more on Veeva Vault Submissions Publishing: veeva.com/Publishing
For more on Veeva Vault RIM: veeva.com/RIM
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystemsAbout Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 475 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit veeva.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.